Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN

Key Points

• Hussman Strategic Advisors bought a new stake of 105,000 Arvinas shares in Q4 (about $1.245M), and institutional investors now hold roughly 95.19% of the company's stock.
• Arvinas missed expectations in its latest quarter—EPS of ($1.10) vs. a ($0.55) estimate—and revenue plunged 84% year-over-year to $9.5 million (consensus $37.3M).
• Insiders have been selling recently (63,864 shares sold in the last 90 days; insiders own 4.73%), and analysts are mixed with a consensus "Hold" rating and an average target of $14.13.

Hussman Strategic Advisors Inc. bought a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 105,000 shares of the company's stock, valued at approximately $1,245,000. Hussman Strategic Advisors Inc. owned 0.16% of Arvinas as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. TCG Crossover Management LLC acquired a new position in shares of Arvinas during the 3rd quarter valued at $13,780,000. Qube Research & Technologies Ltd lifted its position in shares of Arvinas by 154.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company's stock valued at $12,668,000 after acquiring an additional 903,337 shares during the period. Millennium Management LLC increased its stake in Arvinas by 208.4% during the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company's stock valued at $9,198,000 after purchasing an additional 885,483 shares in the last quarter. Balyasny Asset Management L.P. increased its stake in Arvinas by 469.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company's stock valued at $10,286,000 after purchasing an additional 995,125 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in Arvinas by 114.3% during the 3rd quarter. Armistice Capital LLC now owns 1,200,000 shares of the company's stock valued at $10,224,000 after purchasing an additional 640,000 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Insider Transactions at Arvinas

In other news, CEO Randy Teel sold 4,786 shares of the company's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $12.16, for a total value of $58,197.76. Following the completion of the sale, the chief executive officer owned 149,696 shares in the company, valued at $1,820,303.36. This represents a 3.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Noah Berkowitz sold 6,435 shares of the company's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $11.10, for a total transaction of $71,428.50. Following the completion of the sale, the insider owned 202,503 shares of the company's stock, valued at approximately $2,247,783.30. The trade was a 3.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 63,864 shares of company stock worth $802,443. 4.73% of the stock is owned by insiders.

Arvinas Price Performance

NASDAQ ARVN opened at $10.51 on Monday. Arvinas, Inc. has a 1 year low of $5.90 and a 1 year high of $14.51. The firm has a market cap of $672.22 million, a price-to-earnings ratio of -8.21 and a beta of 1.79. The company has a fifty day moving average price of $11.54 and a 200-day moving average price of $11.66.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. During the same quarter in the previous year, the company earned ($0.63) EPS. The business's revenue was down 84.0% compared to the same quarter last year. On average, research analysts anticipate that Arvinas, Inc. will post -3.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ARVN. Wall Street Zen lowered shares of Arvinas from a "hold" rating to a "sell" rating in a research note on Monday, March 2nd. Wedbush boosted their price target on shares of Arvinas from $9.00 to $11.00 and gave the company a "neutral" rating in a research note on Tuesday, February 24th. Zacks Research lowered shares of Arvinas from a "hold" rating to a "strong sell" rating in a research note on Monday, April 27th. Piper Sandler restated an "overweight" rating and set a $20.00 price target (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Finally, BTIG Research boosted their price target on shares of Arvinas from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, March 19th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $14.13.

Arvinas Profile

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.